Verve Therapeutics Inc. (VERV)
Company Description
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases.
Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver.
The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver.
It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College.
The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019.
Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| IPO Date | Jun 17, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 255 |
| CEO | Dr. Sekar Kathiresan M.D. |
Contact Details
Address: 500 Technology Square Cambridge, Massachusetts United States | |
| Website | https://www.vervetx.com |
Stock Details
| Ticker Symbol | VERV |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001840574 |
| CUSIP Number | 92539P101 |
| ISIN Number | US92539P1012 |
| Employer ID | 82-4800132 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Sekar Kathiresan M.D. | Co-Founder, Chief Executive Officer & Director |
| Andrew D. Ashe J.D. | President, Chief Operating Officer & General Counsel |
| Dr. Anthony Philippakis M.D., Ph.D. | Co-Founder & Scientific Advisory Board Member |
| Dr. Barry S. Ticho FACC, M.D., Ph.D. | Co-Founder |
| Dr. Burt A. Adelman M.D. | Co-Founder & Independent Chairman of the Board |
| Dr. J. Keith Joung M.D., Ph.D. | Co-Founder |
| Dr. Kiran Musunuru M.D., M.P.H., Ph.D. | Co-Founder |
| Dr. Troy Lister Ph.D. | Chief Scientific Officer |
| Issi Rozen M.B.A. | Co-Founder & Strategic Advisor |
| Joan Nickerson M.B.A. | Chief Administrative Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 27, 2025 | POS AM | Filing |
| Feb 27, 2025 | S-8 | Filing |
| Feb 27, 2025 | 10-K | Annual Report |
| Feb 27, 2025 | POSASR | Filing |
| Feb 27, 2025 | 8-K | Current Report |
| Feb 05, 2025 | SCHEDULE 13G | Filing |
| Jan 31, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Jan 10, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Jan 10, 2025 | 4 | Filing |
| Jan 10, 2025 | 4 | Filing |